Simultaneous quantification of fludarabine and cyclophosphamide in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry. 2005

L H H Silvertand, and F Vazvaei, and P Weigl, and H Rosing, and M J X Hillebrand, and M J van Maanen, and J H Beijnen
Department of Pharmacy and Pharmacology, Slotervaart Hospital/The Netherlands Cancer Institute, Louwesweg 6, 1066 EC Amsterdam, The Netherlands.

Fludarabine and cyclophosphamide are anticancer agents mainly used in the treatment of hematologic malignancies. We have developed and validated an assay using high-performance liquid chromatography (HPLC) coupled with electrospray ionization tandem mass spectrometry for the quantification of fludarabine in combination with cyclophosphamide in human heparin and human EDTA plasma. Sample pre-treatment consisted of a protein precipitation with cold acetonitrile (-20 degrees C) using 250 microL of plasma. Separation was performed on an Extend C18 column (150 x 2.1 mm i.d.; 5 microm) with a stepwise gradient using 1 mM ammonia solution and acetonitrile at a flow rate of 400 microL/min. The analytical run time was 12 min. The triple quadrupole mass spectrometer was operated in the positive ion mode and multiple reaction monitoring was used for drug quantification. The method was validated over a concentration range of 1 to 100 ng/mL for fludarabine and cyclophosphamide in human heparin and human EDTA plasma. The coefficients of variation were <13.9% for inter- and intra-day precisions. Mean accuracies were also within the designated limits (+/-15%). The analytes were stable in plasma, processed extracts and in stock solution under all relevant conditions.

UI MeSH Term Description Entries
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D012680 Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed) Specificity,Sensitivity,Specificity and Sensitivity
D014740 Vidarabine A nucleoside antibiotic isolated from Streptomyces antibioticus. It has some antineoplastic properties and has broad spectrum activity against DNA viruses in cell cultures and significant antiviral activity against infections caused by a variety of viruses such as the herpes viruses, the VACCINIA VIRUS and varicella zoster virus. Adenine Arabinoside,Ara-A,Arabinofuranosyladenine,Arabinosyladenine,9-beta-Arabinofuranosyladenine,9-beta-D-Arabinofuranosyladenine,Ara A,Vira-A,alpha-Ara A,alpha-D-Arabinofuranosyladenine,beta-Ara A,9 beta Arabinofuranosyladenine,9 beta D Arabinofuranosyladenine,Arabinoside, Adenine,Vira A,ViraA,alpha Ara A,alpha D Arabinofuranosyladenine,beta Ara A
D015203 Reproducibility of Results The statistical reproducibility of measurements (often in a clinical context), including the testing of instrumentation or techniques to obtain reproducible results. The concept includes reproducibility of physiological measurements, which may be used to develop rules to assess probability or prognosis, or response to a stimulus; reproducibility of occurrence of a condition; and reproducibility of experimental results. Reliability and Validity,Reliability of Result,Reproducibility Of Result,Reproducibility of Finding,Validity of Result,Validity of Results,Face Validity,Reliability (Epidemiology),Reliability of Results,Reproducibility of Findings,Test-Retest Reliability,Validity (Epidemiology),Finding Reproducibilities,Finding Reproducibility,Of Result, Reproducibility,Of Results, Reproducibility,Reliabilities, Test-Retest,Reliability, Test-Retest,Result Reliabilities,Result Reliability,Result Validities,Result Validity,Result, Reproducibility Of,Results, Reproducibility Of,Test Retest Reliability,Validity and Reliability,Validity, Face
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D017338 Cladribine An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. 2-Chloro-2'-deoxyadenosine,2-Chlorodeoxyadenosine,2'-Deoxy-2-chloroadenosine,Leustatin
D021241 Spectrometry, Mass, Electrospray Ionization A mass spectrometry technique used for analysis of nonvolatile compounds such as proteins and macromolecules. The technique involves preparing electrically charged droplets from analyte molecules dissolved in solvent. The electrically charged droplets enter a vacuum chamber where the solvent is evaporated. Evaporation of solvent reduces the droplet size, thereby increasing the coulombic repulsion within the droplet. As the charged droplets get smaller, the excess charge within them causes them to disintegrate and release analyte molecules. The volatilized analyte molecules are then analyzed by mass spectrometry. ESI Mass Spectrometry,Electrospray Ionization Mass Spectrometry,Mass Spectrometry, ESI,Spectrometry, ESI Mass

Related Publications

L H H Silvertand, and F Vazvaei, and P Weigl, and H Rosing, and M J X Hillebrand, and M J van Maanen, and J H Beijnen
February 2014, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences,
L H H Silvertand, and F Vazvaei, and P Weigl, and H Rosing, and M J X Hillebrand, and M J van Maanen, and J H Beijnen
January 2010, Journal of AOAC International,
L H H Silvertand, and F Vazvaei, and P Weigl, and H Rosing, and M J X Hillebrand, and M J van Maanen, and J H Beijnen
July 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences,
L H H Silvertand, and F Vazvaei, and P Weigl, and H Rosing, and M J X Hillebrand, and M J van Maanen, and J H Beijnen
February 2003, Journal of mass spectrometry : JMS,
L H H Silvertand, and F Vazvaei, and P Weigl, and H Rosing, and M J X Hillebrand, and M J van Maanen, and J H Beijnen
May 2008, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences,
L H H Silvertand, and F Vazvaei, and P Weigl, and H Rosing, and M J X Hillebrand, and M J van Maanen, and J H Beijnen
October 2005, Journal of pharmaceutical and biomedical analysis,
L H H Silvertand, and F Vazvaei, and P Weigl, and H Rosing, and M J X Hillebrand, and M J van Maanen, and J H Beijnen
November 2005, Biomedical chromatography : BMC,
L H H Silvertand, and F Vazvaei, and P Weigl, and H Rosing, and M J X Hillebrand, and M J van Maanen, and J H Beijnen
May 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences,
L H H Silvertand, and F Vazvaei, and P Weigl, and H Rosing, and M J X Hillebrand, and M J van Maanen, and J H Beijnen
December 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences,
L H H Silvertand, and F Vazvaei, and P Weigl, and H Rosing, and M J X Hillebrand, and M J van Maanen, and J H Beijnen
August 2006, Biomedical chromatography : BMC,
Copied contents to your clipboard!